Sarwar Muhammad Rehan, McDonald Vanessa Marie, Abramson Michael John, Paul Eldho, George Johnson
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
National Health and Medical Research Council Centre for Research Excellence in Severe Asthma and Centre of Excellence in Treatable Traits, The University of Newcastle, Callaghan, Australia.
ERJ Open Res. 2021 May 31;7(2). doi: 10.1183/23120541.00934-2020. eCollection 2021 Apr.
"Treatable traits (TTs)" is a precision medicine approach for facilitating multidimensional assessment of every patient with chronic airway disease, in order to determine the core traits associated with disease outcomes where targeted treatments may be applied.
To determine the prevalence of TTs in chronic obstructive pulmonary disease (COPD) and which traits predict future decline in lung function and quality of life (QoL).
A 4-year longitudinal evaluation was conducted using data from 3726 participants in the English Longitudinal Study of Ageing (ELSA). TTs were identified based on published recommendations. Traits that predicted decline in lung function and QoL were analysed using generalised estimating equations.
Overall, 21 TTs, including pulmonary (n=5), extra-pulmonary (n=13) and behavioural/lifestyle risk-factors (n=3) were identified. In multivariate analyses, the traits of chronic bronchitis (β -0.186, 95% CI -0.290 to -0.082), breathlessness (β -0.093, 95% CI -0.164 to -0.022), underweight (β -0.216, 95% CI -0.373 to -0.058), sarcopenia (β -0.162, 95% CI -0.262 to -0.061) and current smoking (β -0.228, 95% CI -0.304 to -0.153) predicted decline in forced expiratory volume in 1 s (FEV). Of the seven traits that predicted decline in QoL, depression (β -7.19, 95% CI -8.81 to -5.57) and poor family and social support (β -5.12, 95% CI -6.65 to -3.59) were the strongest.
The core TTs of COPD associated with a decline in lung function and QoL were identified. Targeting these impactful traits with individualised treatment using a precision medicine approach may improve outcomes in people with COPD.
“可治疗特征(TTs)”是一种精准医学方法,用于促进对每一位慢性气道疾病患者进行多维度评估,以确定与疾病结局相关的核心特征,从而应用针对性治疗。
确定慢性阻塞性肺疾病(COPD)中可治疗特征的患病率,以及哪些特征可预测未来肺功能和生活质量(QoL)的下降。
使用英国老年纵向研究(ELSA)中3726名参与者的数据进行了为期4年的纵向评估。根据已发表的建议确定可治疗特征。使用广义估计方程分析预测肺功能和生活质量下降的特征。
总体而言,共确定了21种可治疗特征,包括肺部特征(n = 5)、肺外特征(n = 13)和行为/生活方式风险因素(n = 3)。在多变量分析中,慢性支气管炎(β -0.186,95% CI -0.290至-0.082)、呼吸困难(β -0.093,95% CI -0.164至-0.022)、体重过轻(β -0.216,95% CI -0.373至-0.058)、肌肉减少症(β -0.162,95% CI -0.262至-0.061)和当前吸烟(β -0.228,95% CI -0.304至-0.153)可预测1秒用力呼气容积(FEV)下降。在预测生活质量下降的7种特征中,抑郁(β -7.19,95% CI -8.81至-5.57)和家庭及社会支持不足(β -5.12,95% CI -6.65至-3.59)最为显著。
确定了与COPD患者肺功能和生活质量下降相关的核心可治疗特征。采用精准医学方法针对这些有影响的特征进行个体化治疗,可能会改善COPD患者的预后。